IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats

Neuroscience Letters

Volumn 425, Issue 3, 2007, Pages 167-172

  Escartin, Carole ^a,b   Boyer, Frédéric ^a,b   Bemelmans, Alexis Pierre ^c   Hantraye, Philippe ^a,b   Brouillet, Emmanuel ^a,b  

^a DIF   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c HÔPITAL OPHTALMIQUE JULES GONIN   (Switzerland)

Author keywords

3 Nitropropionic acid; Huntington's disease; IGF 1; Mitochondrial impairment; Neuroprotection; Striatum

Indexed keywords

3 NITROPROPIONIC ACID; DNA FRAGMENT; RECOMBINANT SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION;

ANIMALS; CELL DEATH; CELL SURVIVAL; CONVULSANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUNTINGTON DISEASE; INJECTIONS, INTRAVENTRICULAR; INSULIN-LIKE GROWTH FACTOR I; MALE; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURONS; NEUROTOXINS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, INBRED LEW; TREATMENT OUTCOME;

EID: 34548802991     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.08.031     Document Type: Article

References (29)

1. Bae B.I., Xu H., Igarashi S., Fujimuro M., Agrawal N., Taya Y., Hayward S.D., Moran T.H., Montell C., Ross C.A., Snyder S.H., and Sawa A. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47 (2005) 29-41
2. Bantubungi K., Jacquard C., Greco A., Pintor A., Chtarto A., Tai K., Galas M.C., Tenenbaum L., Deglon N., Popoli P., Minghetti L., Brouillet E., Brotchi J., Levivier M., Schiffmann S.N., and Blum D. Minocycline in phenotypic models of Huntington's disease. Neurobiol. Dis. 18 (2005) 206-217
3. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23 (2000) 298-304
4. Benchoua A., Trioulier Y., Zala D., Gaillard M.C., Lefort N., Dufour N., Saudou F., Elalouf J.M., Hirsch E., Hantraye P., Deglon N., and Brouillet E. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell 17 (2006) 1652-1663
5. Bizat N., Hermel J., Boyer F., Jacquard C., Creminon C., Ouary S., Escartin C., Hantraye P., Kajewski S., and Brouillet E. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J. Neurosci. 23 (2003) 5020-5030
6. Brouillet E., Conde F., Beal M.F., and Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59 (1999) 427-468
7. Brouillet E., Jacquard C., Bizat N., and Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 95 (2005) 1521-1540
8. Carrascosa C., Torres-Aleman I., Lopez-Lopez C., Carro E., Espejo L., Torrado S., and Torrado J.J. Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration. Biomaterials 25 (2004) 707-714
9. Carro E., Trejo J.L., Busiguina S., and Torres-Aleman I. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J. Neurosci. 21 (2001) 5678-5684
10. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., and Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8 (2002) 1390-1397
11. Carro E., Trejo J.L., Nunez A., and Torres-Aleman I. Brain repair and neuroprotection by serum insulin-like growth factor I. Mol. Neurobiol. 27 (2003) 153-162
12. Escartin C., Boyer F., Bemelmans A.P., Hantraye P., and Brouillet E. Insulin growth factor-1 protects against excitotoxicity in the rat striatum. Neuroreport 15 (2004) 2251-2254
13. Farrer L.A. Diabetes mellitus in Huntington disease. Clin. Genet. 27 (1985) 62-67
14. Greene J.G., and Greenamyre J.T. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J. Neurochem. 64 (1995) 430-436
15. Humbel R.E. Insulin-like growth factors I and II. Eur. J. Biochem. 190 (1990) 445-462
16. Humbert S., Bryson E.A., Cordelieres F.P., Connors N.C., Datta S.R., Finkbeiner S., Greenberg M.E., and Saudou F. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2 (2002) 831-837
17. Humbert S., and Saudou F. Neuronal death in Huntington's disease: multiple pathways for one issue?. In: Christen H.G.M. (Ed). Neuronal Death by Accident or by Design (2001), Springer-Verlag Berlin Heidelberg, Berlin 137-152
18. Hurlbert M.S., Zhou W., Wasmeier C., Kaddis F.G., Hutton J.C., and Freed C.R. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48 (1999) 649-651
19. 2+ entry during NMDA receptor activation. FASEB J. 20 (2006) 1021-1023
20. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., and Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
21. Liu X.F., Fawcett J.R., Thorne R.G., DeFor T.A., and Frey II W.H. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J. Neurol. Sci. 187 (2001) 91-97
22. Matthews R.T., Yang L., Jenkins B.G., Ferrante R.J., Rosen B.R., Kaddurah-Daouk R., and Beal M.F. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 18 (1998) 156-163
23. Mittoux V., Ouary S., Monville C., Lisovoski F., Poyot T., Conde F., Escartin C., Robichon R., Brouillet E., Peschanski M., and Hantraye P. Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J. Neurosci. 22 (2002) 4478-4486
24. Palfi S., Riche D., Brouillet E., Guyot M.C., Mary V., Wahl F., Peschanski M., Stutzmann J.M., and Hantraye P. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Exp. Neurol. 146 (1997) 135-141
25. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., and Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5 (2002) 731-736
26. Schneider H.J., Pagotto U., and Stalla G.K. Central effects of the somatotropic system. Eur. J. Endocrinol. 149 (2003) 377-392
27. The Huntington study group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group, Cell, 72 (1993) pp. 971-983.
28. Walker F.O., and Raymond L.A. Targeting energy metabolism in Huntington's disease. Lancet 364 (2004) 312-313
29. Woelfle J., Chia D.J., Massart-Schlesinger M.B., Moyano P., and Rotwein P. Molecular physiology, pathology, and regulation of the growth hormone/insulin-like growth factor-I system. Pediatr. Nephrol. 20 (2005) 295-302